Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prostate cancer: update].

Stéphane Oudard1, Jacques Medioni, Florian Scotté

  • 1Département de cancérologie médicale, Hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris. stephane.oudard@hop.egp.ap-hopparisfr>

Bulletin Du Cancer
|November 4, 2005
PubMed
Summary

This study highlights that elevated pAkt and reduced pERK signal transduction are linked to biological relapse in prostate cancer. Early radiotherapy and docetaxel-based treatments show improved survival and reduced relapse rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemotherapy-induced nausea and vomiting in the literature: a cross-sectional analysis by time and emetogenicity.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same author

Editorial.

Current opinion in oncology·2026
Same author

Comparing clinical practice guidelines on the prevention and management of chemotherapy-induced hand-foot syndrome.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Multi-disciplinarity in cancer care: a call for a global framework to deliver equitable and effective supportive care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Mitotic signal transduction pathways, including pAkt and pERK, play a role in cancer progression.
  • Prostate cancer management involves surgery, radiotherapy, and chemotherapy, with ongoing research into novel therapeutic strategies.

Purpose of the Study:

  • To investigate the association between specific molecular markers (pAkt, pERK) and biological relapse in prostate cancer.
  • To evaluate the efficacy of different treatment modalities, including radiotherapy and docetaxel-based chemotherapy, in managing prostate cancer.
  • To explore the potential of novel agents and combinations in improving treatment outcomes.

Main Methods:

  • Analysis of mitotic signal transduction markers (pAkt, pERK) in relation to biological relapse.

Related Experiment Videos

  • Comparison of immediate versus deferred radiotherapy for high-risk localized prostate cancer (T1-3 N0M0).
  • Review of Phase III randomized clinical trials (TAX-327, SWOG 99-16) evaluating docetaxel and combination therapies.

    • Main Results:

    • Overexpression of pAkt and reduced pERK expression are associated with biological relapse.
    • Immediate radiotherapy significantly reduced local relapse rates and improved progression-free survival compared to deferred radiotherapy.
    • Docetaxel, particularly every 21 days, demonstrated improved overall survival, progression-free survival, and pain reduction.
    • Combination of docetaxel with estramustine showed improved PSA response and progression-free survival but increased embolic toxicity.
    • Addition of thalidomide to docetaxel improved progression-free and overall survival.
    • Bortezomib showed PSA responses as monotherapy, while imatinib did not.

    Conclusions:

    • Specific molecular markers can predict biological relapse in prostate cancer.
    • Early radiotherapy is beneficial for high-risk localized disease.
    • Docetaxel is a reference treatment for advanced prostate cancer, with ongoing research into optimizing its use and combination therapies.
    • Novel agents like thalidomide and bortezomib show promise in prostate cancer treatment, warranting further investigation.